i
n
f
l
a
r
x
Loading
Loading
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned.